Acquisition of the Habitrol Brand From Novartis

We are happy to announce that we have received consent from the U.S. Federal Trade Commission for our acquisition of the Habitrol® brand, an over-the-counter nicotine replacement therapy transdermal patch from Novartis Consumer Health Inc.

PRESS RELEASE

We are happy to announce that we have received consent from the U.S. Federal Trade Commission (FTC) for our acquisition of the Habitrol® brand, an over-the-counter nicotine replacement therapy transdermal patch from Novartis Consumer Health Inc.

The Habitrol® patch is intended for use by habitual smokers to help with reducing withdrawal symptoms, including nicotine craving, associated with quitting smoking. The patch gradually delivers controlled amounts of nicotine through the body that are lower than the amount in cigarettes.

We had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol® brand and to market the product in the U.S. market. With the completion of this acquisition, we have assumed responsibility for the product and will commence shipments of the product in the market soon, because Good Health Can’t Wait.

Click here to read more